CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition.
Cancer Cell. 2022 Nov 14;40(11):1341-1357.e13. doi: 10.1016/j.ccell.2022.10.015.
Cancer Cell. 2022.
PMID: 36379207